Sandoz Archives | Page 2 of 3

Home / Posts tagged Sandoz (Page 2)

Sandoz Opens New Antibiotic Production Facility in Austria, to Significantly Increase Capacity for Life-saving Medicines

EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000m2 means Kundl can now manufacture 240 million packages per year Represents capacity increase of 20% over 2023 and more than doubling from 2021 output levels Automation and innovative technologies allow production [...]

Sandoz Reports Fourth Quarter 2023 Sales and Full-year 2023 Results

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Strong fourth quarter performance, with net sales1 of USD 2.5 billion, up 10% in constant currencies (up 11% in USD) Full-year 2023 net sales of USD 9.6 billion, up 7% in constant currencies (up 6% in USD) Strong growth across all three regions and double-digit [...]

Sandoz Receives FDA Approval for First and Only Denosumab Biosimilars

Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all indications of reference medicines Xgeva ®* (denosumab) and Prolia®* (denosumab) FDA approval based on robust clinical studies and totality of evidence, which show no clinically meaningful differences from reference medicines Basel, March 5, 2024 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, [...]

Sandoz Announces Nominations to the Board of Directors and Leadership Change

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting Remco Steenbergen appointed as Sandoz CFO and member of Executive Committee as of July 1, 2024, and consequently not standing for [...]

Sandoz Acquires CIMERLI® Business from Coherus, Further Building Biosimilar and Ophthalmology Leadership in US Market

CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indications Dedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for providers and patients Basel, March 4, 2024 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar CIMERLI®* [...]

Sandoz US Subsidiaries Resolve Generic Drug Antitrust Class Action Litigation with Direct Purchaser Class Plaintiffs

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Sandoz US to pay USD 265 million in exchange for full release of all claims by the class Resolves all federal antitrust damages for direct purchaser class plaintiffs’ claims in this litigation, if approved by Court Basel, February 29, 2024 – Sandoz [...]

Sandoz Announces Changes in the Board of Directors

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual General Meeting François-Xavier Roger announced to pursue a new executive responsibility and therefore to step down from the Sandoz Board of Directors post publication [...]

Sandoz Launches First and Only Biosimilar for Multiple Sclerosis, Tyruko® (natalizumab), in Germany

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multiple sclerosis (RRMS) Launch strengthens well-established Sandoz biosimilar portfolio in Europe Basel, January 31, 2024 (Korea Bizwire) – [...]

Sandoz Announces Agreement to Acquire CIMERLI® Business from Coherus, Strengthening Position in US Market

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab-injection) for all approved indications Acquisition strengthens Sandoz ophthalmology portfolio Basel, January 22, 2024 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US [...]

Sandoz Launches Hyrimoz® (adalimumab) High-concentration Formulation in Europe, Aiming to Improve Patient Care

Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) indicated for all conditions of reference medicine Humira®* Hyrimoz® HCF to launch progressively across Europe Hyrimoz® HCF strengthens well-established Sandoz biosimilar immunology portfolio in Europe Basel, November 21, 2023 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; [...]